ImmunoPrecise Antibodies Stock Price, News & Analysis (NASDAQ:IPA) $1.70 +0.13 (+8.28%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.51▼$1.7550-Day Range$1.14▼$2.3052-Week Range$1.14▼$5.90Volume47,464 shsAverage Volume60,405 shsMarket Capitalization$42.59 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media ImmunoPrecise Antibodies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside370.6% Upside$8.00 Price TargetShort InterestHealthy0.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.35) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.32 out of 5 starsMedical Sector284th out of 949 stocksPharmaceutical Preparations Industry117th out of 442 stocks 3.5 Analyst's Opinion Consensus RatingImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, ImmunoPrecise Antibodies has a forecasted upside of 370.6% from its current price of $1.70.Amount of Analyst CoverageImmunoPrecise Antibodies has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.12% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently decreased by 38.30%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunoPrecise Antibodies does not currently pay a dividend.Dividend GrowthImmunoPrecise Antibodies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPA. Previous Next 2.9 News and Social Media Coverage News SentimentImmunoPrecise Antibodies has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ImmunoPrecise Antibodies this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for IPA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.Percentage Held by InstitutionsOnly 5.71% of the stock of ImmunoPrecise Antibodies is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.35) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoPrecise Antibodies is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoPrecise Antibodies is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoPrecise Antibodies has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Read More IPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPA Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Sees Significant Decline in Short InterestNovember 27, 2023 | businesswire.comImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release CallDecember 1, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 22, 2023 | finance.yahoo.comImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug DiscoveryNovember 20, 2023 | benzinga.comImmunoPrecise's BioStrand® Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug DiscoveryOctober 25, 2023 | stockhouse.comIPA's Subsidiary, BioStrand, Provides an Update on LENSai(TM)October 25, 2023 | benzinga.comIPA's Subsidiary, BioStrand, Provides an Update on LENSai™October 25, 2023 | financialpost.comIPA’s Subsidiary, BioStrand, Provides an Update on LENSai™December 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 20, 2023 | finance.yahoo.comOvercoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological DataOctober 20, 2023 | finance.yahoo.comHow ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody ResearchSeptember 19, 2023 | finance.yahoo.comImmunoPrecise Antibodies Announces CFO TransitionSeptember 18, 2023 | nasdaq.comHC Wainwright & Co. Reiterates ImmunoPrecise Antibodies (IPA) Buy RecommendationSeptember 18, 2023 | markets.businessinsider.comImmunoPrecise Antibodies (IPA) Receives a Buy from H.C. WainwrightSeptember 17, 2023 | finance.yahoo.comImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2024 Earnings Call TranscriptSeptember 5, 2023 | finance.yahoo.comIPA Announces Board RefreshmentAugust 9, 2023 | finance.yahoo.comIPA Responds to 13D FilingJuly 7, 2023 | finance.yahoo.comImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023July 6, 2023 | msn.comImmunoPrecise Antibodies's Earnings OutlookJune 29, 2023 | finance.yahoo.comIPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.May 30, 2023 | finance.yahoo.comIPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems BiologyMay 17, 2023 | finance.yahoo.comIPA to Present at Jefferies Healthcare Conference 2023April 18, 2023 | benzinga.comTheStreetReports: Disruptive Technology Stocks in Focus – KAVL, SONM, PBTS, IPAMarch 30, 2023 | finance.yahoo.comImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with AstellasMarch 29, 2023 | stockhouse.comEuropean Patent Office to Grant BioKey's Patent Application for Foundational HYFT® TechnologyMarch 27, 2023 | finance.yahoo.comEuropean Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® TechnologyMarch 23, 2023 | finance.yahoo.comImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival RatesSee More Headlines Receive IPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/14/2023Today12/01/2023Next Earnings (Estimated)12/21/2023Fiscal Year End4/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IPA CUSIPN/A CIK1715925 Webwww.immunoprecise.com Phone250-483-0308FaxN/AEmployees102Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$9.00 Low Stock Price Target$7.00 Potential Upside/Downside+370.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,980,000.00 Net Margins-95.81% Pretax Margin-100.04% Return on Equity-35.22% Return on Assets-25.84% Debt Debt-to-Equity Ratio0.16 Current Ratio2.45 Quick Ratio2.10 Sales & Book Value Annual Sales$15.61 million Price / Sales2.73 Cash FlowN/A Price / Cash FlowN/A Book Value$1.74 per share Price / Book0.98Miscellaneous Outstanding Shares25,050,000Free Float23,339,000Market Cap$42.59 million OptionableNot Optionable Beta0.32 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Ilse RoodinkChief Scientific Officer & Interim General Manager of IPA Europe, OssDr. Barry Neil DuplantisVice President of Client RelationsMs. Kristin Taylor CPAM.B.A., Chief Financial OfficerMr. David E. OrtonChief Operating OfficerDr. Roland RomijnHead of General Operations of the Utrecht site of IPA (Europe)Key CompetitorsMinerva NeurosciencesNASDAQ:NERVRain OncologyNASDAQ:RAINSocietal CDMONASDAQ:SCTLCytoMed TherapeuticsNASDAQ:GDTCMEI PharmaNASDAQ:MEIPView All CompetitorsInstitutional OwnershipRathbones Group PLCBought 14,000 shares on 11/13/2023Ownership: 0.056%Ingalls & Snyder LLCSold 31,802 shares on 11/2/2023Ownership: 4.105%View All Institutional Transactions IPA Stock Analysis - Frequently Asked Questions Should I buy or sell ImmunoPrecise Antibodies stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPA shares. View IPA analyst ratings or view top-rated stocks. What is ImmunoPrecise Antibodies' stock price target for 2024? 2 Wall Street analysts have issued 1 year price targets for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $7.00 to $9.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 370.6% from the stock's current price. View analysts price targets for IPA or view top-rated stocks among Wall Street analysts. How have IPA shares performed in 2023? ImmunoPrecise Antibodies' stock was trading at $5.21 at the beginning of the year. Since then, IPA stock has decreased by 67.4% and is now trading at $1.70. View the best growth stocks for 2023 here. Are investors shorting ImmunoPrecise Antibodies? ImmunoPrecise Antibodies saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 29,000 shares, a decline of 38.3% from the October 31st total of 47,000 shares. Based on an average trading volume of 65,100 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are sold short. View ImmunoPrecise Antibodies' Short Interest. When is ImmunoPrecise Antibodies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, December 21st 2023. View our IPA earnings forecast. How were ImmunoPrecise Antibodies' earnings last quarter? ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) released its quarterly earnings data on Thursday, September, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06. The company earned $4.26 million during the quarter, compared to analysts' expectations of $3.98 million. ImmunoPrecise Antibodies had a negative net margin of 95.81% and a negative trailing twelve-month return on equity of 35.22%. Who are ImmunoPrecise Antibodies' major shareholders? ImmunoPrecise Antibodies' stock is owned by many different retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.10%), Rathbones Group PLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of ImmunoPrecise Antibodies? Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:IPA) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.